The global genito-urinary drugs market size is expected to grow from $40.40 billion in 2021 to $42.75 billion in 2022 at a compound annual growth rate (CAGR) of 5.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The genito-urinary drugs market is expected to reach $63.83 billion in 2026 at a CAGR of 10.5%.
What is the Global Genito-Urinary Drugs Market?
The genito-urinary drugs market consists of sales of genito-urinary drugs and related services by entities (organizations, sole traders and partnerships) that produce genito-urinary drugs to treat genito- urinary diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, Reno vascular diseases, benign prostate diseases, and other related diseases. This industry includes establishments that produce infertility drugs, hormonal contraceptives, erectile dysfunction drugs and hormonal replacement drugs to treat infertility, infections and prevent pregnancy. It also consists of establishments which produce drugs for benign prostatic hypertrophy, drugs for urinary incontinence and overactive bladder, diuretics to treat urinary calculi, glomerular disorders and other urinary disorders.
Get a Sample of the global genito-urinary drugs market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3144&type=smp
What drives the Global Genito-Urinary Drugs Market?
The aging population profile of most countries contributed to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period.
Get the full global genito-urinary drugs industry report here:
https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report
Global Genito-Urinary Drugs Market Segments
The global genito-urinary drugs market is segmented:
By Type: Hormonal Contraceptives, Drugs for Benign Prostatic Hypertrophy, Drugs for Infertility, Drugs for Erectile Dysfunction, Drugs for Urinary Incontinence and Overactive Bladder, Drugs for Infections and Others, Drugs for Hormonal Replacement Therapy, Diuretics
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others
By Route of Administration: Oral, Parenteral, Others
By Drug Classification: Branded Drugs, Generic Drugs
By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Dru
By Geography: The regions covered in the genito-urinary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Genito-Urinary Drugs Global Market Report 2022provides market size and growth forecasts for the global genito-urinary drugs market, global genito-urinary drugs market share, genito-urinary drugs market segments and geographies, genito-urinary drugs market competitive landscape including leading competitors’ revenues, profiles and market shares. The genito-urinary drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Global Genito-Urinary Drugs Industry Playersinclude Sanofi S.A, GlaxoSmithKline, AstraZeneca, AbbVie, Reckitt, Benckiser Group plc, Astellas Pharma Inc., Otsuka Holdings Co ltd, Pfizer Inc., Merck KGaA and Daiichi Sankyo Company. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.
